Quantum BioPharma Announces $750 Private Placement to Key Insiders, Restoring Voting Control

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced a non-brokered private placement of up to 30 Class A multiple voting shares at $25 per share, generating gross proceeds of up to $750. The offering, approved by shareholders on September 26, 2025, is expected to be fully subscribed by entities controlled by Zeeshan Saeed and Anthony Durkacz, two key figures within the company's leadership structure.

This transaction carries significant implications for corporate governance and shareholder voting dynamics. Upon completion of the placement, the voting rights attached to the Class A shares will increase to 75.27%, effectively restoring them to nearly their original level when Quantum BioPharma went public in 2018. This consolidation of voting power represents a substantial shift in control back to the company's founding leadership, potentially streamlining decision-making processes but also concentrating authority among a small group of insiders.

The biopharmaceutical company, which focuses on developing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, intends to use the proceeds for general working capital purposes. This funding comes at a critical time for the company's research and development pipeline, particularly for its lead compound Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Myelin degradation represents the underlying mechanism of multiple sclerosis, making this research potentially transformative for patients suffering from this debilitating condition.

Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum BioPharma maintains its primary focus on advancing Lucid-MS through various development stages. The company's broader portfolio includes strategic investments through FSD Strategic Investments Inc., which represents loans secured by residential or commercial property, providing additional financial stability beyond its pharmaceutical research activities.

Quantum BioPharma also maintains significant financial interests in Unbuzzd Wellness Inc., formerly known as Celly Nutrition Corp., where it retains ownership of 20.11% as of March 31, 2025. The agreement includes royalty payments of 7% of sales from the unbuzzd(TM) product until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity. The company retains full rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses, preserving its strategic flexibility in the wellness and pharmaceutical markets.

For investors seeking additional information about Quantum BioPharma's developments, the company maintains a newsroom at https://ibn.fm/QNTM where updates regarding QNTM are regularly posted. This private placement represents a strategic move to strengthen the company's financial position while consolidating voting control, potentially accelerating decision-making processes as the company advances its promising therapeutic candidates through clinical development stages.